All In Biotech

Drug Trial Radar · NCT00931736

Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness

Last checked: Nov 19, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,031 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,031

Actual

Start

Aug 2009

Primary completion

Apr 2017

Study completion Apr 2017

Sponsor

Lead sponsor
McGill UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR)
First posted
Jul 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

On a global scale, tuberculosis (TB) is the single most important infectious cause of morbidity and mortality. The World Health Organization has estimated that one-third of the entire world's population carries latent TB infection. A key TB control strategy is therapy of latent TB infection (LTBI). The current standard regimen is 9 months of Isoniazid (9INH). This regimen has excellent efficacy if taken regularly, but its effectiveness is substantially reduced by poor compliance. Serious side effects, such as hepato-toxicity can occur. Three shorter alternatives have been recommended: 6 months INH (6INH), 2 months Rifampin - Pyrazinamide (2RIF-PZA) and 4 months Rifampin (4RIF). The regimen of 6INH is less efficacious than 9INH, while 2RIF-PZA has been largely abandoned because of serious toxicity. Based on some evidence in treatment of LTBI, and extrapolating from extensive experience with treatment of active TB, it is believed that 4RIF has similar efficacy as 9INH. Therefore, the investigators are initiating the first multi-site international randomized trial that will compare the effectiveness of 4RIF and 9INH in preventing active tuberculosis.

Conditions

  • Latent Tuberculosis Infection

Interventions

  • IsoniazidDrug

    The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.

  • RifampinDrug

    The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed active TB during 28 months after randomizationTime frame: 7 years total with data analysis

Locations

12 sites in 9 countries. Site status is shown where the registry gives one.

  • Woolcock Institute of Medical Research

    Sydney, New South Wales, Australia

  • Centre de Pneumophthysiologie

    Cotonou, Benin

  • Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde

    Rio de Janeiro, Brazil

  • University of Alberta

    Edmonton, Alberta, Canada

  • British Columbia Centre for Disease Control

    Vancouver, British Columbia, Canada

  • Montreal Chest Institute

    Montreal, Quebec, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Research and Development Unit, Komfo Anokye Teaching Hospital

    Kumasi, Ghana

  • Service de Phtisiologie, Hopital National Ignace Deen

    Conakry, Guinea

  • Health Research Unit, Faculty of Medicine

    Bandung, West Java, Indonesia

  • King Fahad National Guard Hospital

    Riyadh, Saudi Arabia

  • Korean Institute of Tuberculosis

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.